Prescient Therapeutics (ASX:PTX) Long-Term Debt : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Long-Term Debt?

Prescient Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Prescient Therapeutics Long-Term Debt Historical Data

The historical data trend for Prescient Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Long-Term Debt Chart

Prescient Therapeutics Annual Data

Trend

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Long-Term Debt

Get a 7-Day Free Trial

Prescient Therapeutics Semi-Annual Data
	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Prescient Therapeutics (ASX:PTX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Prescient Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics Headlines

No Headlines